ULGX Stock Overview
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Urologix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 900.00% |
| 3 Year Change | -98.33% |
| 5 Year Change | -97.56% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ULGX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.2% |
| 1Y | 900.0% | -0.7% | 24.7% |
Return vs Industry: ULGX exceeded the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: ULGX exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| ULGX volatility | |
|---|---|
| ULGX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ULGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ULGX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | n/a | Bryon Merade | www.urologix.com |
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms.
Urologix, Inc. Fundamentals Summary
| ULGX fundamental statistics | |
|---|---|
| Market cap | US$2.13k |
| Earnings (TTM) | -US$4.67m |
| Revenue (TTM) | US$12.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs ULGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULGX income statement (TTM) | |
|---|---|
| Revenue | US$12.00m |
| Cost of Revenue | US$6.34m |
| Gross Profit | US$5.66m |
| Other Expenses | US$10.32m |
| Earnings | -US$4.67m |
Last Reported Earnings
Mar 31, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ULGX perform over the long term?
See historical performance and comparison